Dow Jones
38.675,68 +449,98 (+1,18%) Nasdaq
16.156,33 +315,33 (+1,99%) Nikkei 225
38.236,07 -38,03 (-0,10%) EUR/USD
1,0768 +0,0001 (+0,01%) Bitcoin EUR
59.549,69 +715,98 (+1,22%) CMC Crypto 200
1.328,03 +51,05 (+4,00%)
C4 Therapeutics, Inc. (CCCC)
Dopo ore:
| Chiusura precedente | 6,43 |
| Aperto | 6,70 |
| Denaro | 6,71 x 1000 |
| Lettera | 6,75 x 1000 |
| Min-Max giorno | 6,57 - 6,94 |
| Intervallo di 52 settimane | 1,06 - 11,88 |
| Volume | |
| Media Volume | 2.292.861 |
| Capitalizzazione | 463,751M |
| Beta (5 anni mensile) | 3,19 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,67 |
| Prossima data utili | 06 mag 2024 - 08 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 18,50 |
GlobeNewswireC4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myeloma and Non-Hodgkin’s Lymphoma
CFT8634 Phase 1 Dose Escalation Data to be Presented at the Connective Tissue Oncology Society Annual Meeting on November 2, 2023 CFT7455 Monotherapy Phase 1 Dose Escalation Complete in Relapsed/Refractory Multiple Myeloma; Data to be Presented at a Company-Sponsored Event on December 12, 2023 Phase 1 Dose Escalation Continues to Progress for CFT7455 in Combination with Dexamethasone in Relapsed/Refractory Multiple Myeloma and as a Monotherapy in Non-Hodgkin’s Lymphoma WATERTOWN, Mass., Oct. 11,
GlobeNewswireC4 Therapeutics Announces Chief Financial Officer Succession
Kendra Adams Kendra Adams, Chief Financial Officer WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Kendra Adams as chief financial officer (CFO), effective September 18, 2023. She will succeed Lauren White, who will be
- GlobeNewswire
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Established Exclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC™ Degrader, with Betta Pharmaceuticals in Greater China for NSCLC; U.S. IND Cleared Ongoing Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ Degrader, and CFT8634, a BRD9 BiDAC Degrader, Continue to Progress; Phase 1 Dose Escalation Data Expected 2H 2023 Strengthened Leadership Team with Appointments of Len Reyno, M.D., as Chief Medical Officer, and Mary Christian, Pharm.D., as Senior Vice President, Regulatory Ca
